The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAgronomics Regulatory News (ANIC)

Share Price Information for Agronomics (ANIC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 8.55
Bid: 8.50
Ask: 8.60
Change: -0.46 (-5.31%)
Spread: 0.10 (1.176%)
Open: 8.45
High: 8.56
Low: 8.20
Prev. Close: 8.66
ANIC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

IsraFirst Regulatory Approval for Cultivated Beef

18 Jan 2024 07:00

RNS Number : 0724A
Agronomics Limited
18 January 2024
 

 

 18 January 2024

 Agronomics Ltd

("Agronomics" or the "Company")

 Israel Awards the World's First Regulatory Approval for Cultivated Beef

 

Agronomics (LON: ANIC), a leading listed company in cellular agriculture, is pleased to announce that the Israeli Ministry of Health (IMOH) has granted regulatory approval for the world's first commercial sale of cultivated beef.

Agronomics would like to congratulate Aleph Farms on becoming the first company in the world to gain regulatory approval for its cultivated beef product after the IMOH issued a 'no questions' letter, which allows the company to commercialise its products in Israel. Aleph Farms has also filed for regulatory approval in Singapore, Switzerland, the UK and the US, and is advancing its applications in other markets.

Agronomics is aware of multiple companies, including those within its portfolio, that are expecting regulatory approvals for cultivated meat and seafood products across several markets. Meanwhile, Vow Food is in the middle of a consultation process after its cultured quail was cleared as safe to eat by Food Standards Australia and New Zealand in December 2023. 

These announcements follow Upside Foods and Good Meat, which received regulatory approval for their cultivated chicken products in the US last year.

Jim Mellon, Executive Chairman of Agronomics commented:

"This approval is another significant step forward for our industry and shows the commitment among an increasing number of jurisdictions to find more sustainable production methods to meet the increasing global demand for protein. We look forward to seeing some of Agronomics' portfolio companies achieving this significant milestone in the near future."  

About Agronomics

Agronomics is a leading listed alternative proteins company with a focus on cellular agriculture and cultivated meat. The Company has established a portfolio of 24 companies in this rapidly advancing sector. It seeks to secure minority stakes in companies owning technologies with defensible intellectual property that offer new ways of producing food and materials with a focus on products historically derived from animals. These technologies are driving a major disruption in agriculture, offering solutions to improve sustainability, as well as addressing human health, animal welfare and environmental damage. This disruption will decouple supply chains from the environment and animals, as well as being fundamental to feeding the world's expanding population. A full list of Agronomics' portfolio companies is available at https://agronomics.im/.

 

About Cellular Agriculture

Cellular Agriculture is the production of agriculture products directly from cells, as opposed to raising an animal for slaughter, or growing crops. This encompasses cell culture to produce cultivated meat and materials, and fermentation processes that harness a combination of molecular biology, synthetic biology, tissue engineering and biotechnology to massively simplify production methods in a sustainable manner.

 

Over the coming decades, the source of the world's food supply traditionally derived from conventional agriculture is going to change dramatically. We have already witnessed the first wave of this shift with the consumer adoption of plant-based alternative proteins but today, we are on the cusp of an even bigger wave of change. This is being facilitated by advances in cellular agriculture. This change is necessary, given scientists claims that if we maintain existing animal protein consumption patterns, then we will not meet the Paris Agreement's goal of limiting warming to 1.5?.

 

AT Kearney, a global consultancy firm, projects that cultivated meat's market share will reach 35% by 2040. This combined with the Good Food Institute's estimate that a US $1.8 trillion investment will be required in order to produce just 10% of the world's protein using this technology, means that we are on the cusp of a multi-decade flow of capital to build out manufacturing facilities. Funding in the field of cellular agriculture is accelerating, however still less than US$ 5 billion has been invested worldwide since the industry's inception in 2016.

 

For further information please contact:

Agronomics

Limited

Beaumont

Cornish Limited

Canaccord Genuity Limited

Cavendish Securities Plc

Peterhouse Capital

Limited

SEC Newgate

The Company

Nomad

Joint Broker

Joint Broker

Joint Broker

Public Relations

Jim Mellon

Denham Eke

Roland Cornish

James Biddle

Andrew Potts

Harry Pardoe

Alex Aylen (Head of Equities)

Giles Balleny

Michael Johnson

Lucy Williams

Charles Goodfellow

Ed Orlebar

Alistair Walker

+44 (0) 1624 639396

info@agronomics.im

+44 (0) 207 628 3396

+44 (0) 207 523 8000

+44 (0) 207 397 8900

+44 (0) 207 469 0936

+44 (0) 20 7930 0777

+44 (0) 7738 724 630

agronomics@tbcardew.com

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAMZGMMLNZGDZM
Date   Source Headline
10th Apr 20137:00 amRNSDirector/PDMR Shareholding
9th Apr 20137:00 amRNSNet Asset Value calculation to 31st March 2013
28th Mar 20137:00 amRNSHalf Yearly Report
8th Feb 20134:50 pmRNSDirector Dealing
8th Feb 20134:45 pmRNSReplacement - Director dealing
30th Jan 20139:55 amRNSDirector Dealing
25th Jan 20133:27 pmRNSNet Asset Value
1st Nov 20127:00 amRNSFinal Results
5th Oct 20122:07 pmRNSNet Asset Value
19th Jul 20123:44 pmRNSDirector/PDMR Shareholding
5th Jul 20121:09 pmRNSNet Asset Value
21st Jun 20127:00 amRNSDirector/PDMR Shareholding
18th Jun 20127:00 amRNSDirector/PDMR Shareholding
13th Jun 20127:00 amRNSDirectorate Change
30th May 201211:40 amRNSDirectorate Change
30th May 201211:14 amRNSHolding(s) in Company
11th Apr 20123:50 pmRNSNet Asset Value
30th Mar 20127:00 amRNSHalf Yearly Report
9th Jan 20123:42 pmRNSNet Asset Value
16th Dec 20114:24 pmRNSChange of Quarterly NAV valuation
20th Oct 20111:46 pmRNSDirector/PDMR Shareholding
14th Oct 20114:43 pmRNSDirector/PDMR Shareholding
14th Oct 201110:53 amRNSInvestment Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.